Materials and methods: A retrospective and prospective descriptive study was conducted on 54 recurrent endometrial cancer patients received Paclitaxel Carboplatin in K hospital. Results: The overall response rate was 75, 9%; complete response was 31, 5%; partial response account 44, 4%.